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Dapsone hypersensitivity syndrome causing disseminated intravascular
coagulation
Abstract
Dapsone hypersensitivity syndrome is an idiosyncratic reaction to this drug and can present with different
clinical manifestations of varying severity. We describe a patient with disseminated intravascular
coagulation (DIC) as an adverse reaction to dapsone. To the best of our knowledge, this is the first time it
has been described in the literature. She presented with fever, rash and abdominal pain; she also had
marked eosinophilia and features suggestive of oxidative haemolysis. Her course was complicated by
DIC, splenic infarction and gastrointestinal bleeding. Extensive investigations did not reveal any
alternative aetiology. She was initially treated with supportive measures and folic acid; steroids were
administered later, following clinical deterioration. There was gradual improvement and the steroids were
tapered. The patient recovered fully and remains well; her underlying chronic dermatologic condition is
under satisfactory control with other medications.
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Unexpected outcome (positive or negative) including adverse
drug reactions
Dapsone hypersensitivity syndrome causing disseminated intravascular
coagulation
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SUMMARY
Dapsone hypersensitivity syndrome is an idiosyncratic reaction to this drug and can present with
different clinical manifestations of varying severity. We describe a patient with disseminated
intravascular coagulation (DIC) as an adverse reaction to dapsone. To the best of our knowledge, this is
the first time it has been described in the literature. She presented with fever, rash and abdominal pain;
she also had marked eosinophilia and features suggestive of oxidative haemolysis. Her course was
complicated by DIC, splenic infarction and gastrointestinal bleeding. Extensive investigations did not
reveal any alternative aetiology. She was initially treated with supportive measures and folic acid;
steroids were administered later, following clinical deterioration. There was gradual improvement and
the steroids were tapered. The patient recovered fully and remains well; her underlying chronic
dermatologic condition is under satisfactory control with other medications.

BACKGROUND
This case illustrates the challenges a clinician may face with life threatening adverse reactions from a
medication used commonly in various parts of the world, for a variety of indications by doctors of several
specialties, as well as general physicians and family practitioners.

CASE PRESENTATION
A 44-year-old Chinese woman presented with a 6 day history of fatigue, fever, pruritic rash, nausea and
abdominal pain. Three weeks earlier she was prescribed dapsone 100 mg daily for dermatitis
herpetiformis, which she stopped taking 2 days before admission. Her personal medical and family
history was unremarkable. Examination revealed temperature 40°C, blood pressure 90/50 mm Hg,
bilateral pleural effusions, scleral icterus, tender upper quadrants bilaterally and inguinal
lymphadenopathy. There was a diffuse non-blanching maculopapular exanthem over the abdomen,
arms and legs with sparing of the mucosal areas (fig 1A).
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Figure 1 (A) Exanthem of dapsone hypersensitivity reaction on abdomen. (B) Peripheral blood film
showing oxidative haemolysis. (C) Computed tomographic scan of the abdomen showing splenic
infarction, bilateral pleural effusions and body wall oedema.

INVESTIGATIONS
Laboratory testing showed oxidative haemolysis (fig 1B) (bilirubin 105 µmol/l, lactate dehydrogenase
9
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(LDH) 506 IU/l, reticulocytes 269.2x10 ); neutropenia 0.5x10 /l; eosinophilia 1.97x10 /l (normal range
9
0.04–0.44x10 /l); and elevated alanine aminotransferase (ALT) 432 U/l (normal <45 U/l) and aspartate

transaminase (AST) 129 U/l (normal <45 U/l). Skin biopsy showed moderate interface dermatitis with
negative IgA/G immunofluorescence. The patient had disseminated intravascular coagulation (DIC) with
concurrent splenic infarction (fig 1C), gastrointestinal bleeding and abdominal wall haemorrhage;
international normalised ratio (INR) was 1.6, fibrinogen 1.0 g/l, D-dimers >20 µg/ml, and platelets
112x109/l. Glucose-6-phosphate dehydrogenase (G6PD) value was normal.

DIFFERENTIAL DIAGNOSIS
Thrombotic, septic, vasculitic, and porphyrin screen were negative.

TREATMENT
The patient was managed initially with supportive measures and folic acid. Blood products were not
required. Intravenous steroids were introduced on day 5 in response to rising eosinophilia and worsening
symptoms. There was marked improvement in temperature and exanthem within 48 hours. The
eosinophil count fell to 0.24x109/l.

OUTCOME AND FOLLOW-UP
Oral steroids were tapered over 4 weeks with resolution of exanthem and normalisation of
transaminases. Rechallenge was not attempted, in view of the life threatening initial reaction. The
patient recovered fully and remains well 1 year after her hospitalisation; her underlying chronic
dermatologic condition is under satisfactory control with other medications. Patient consent was

obtained for publication of clinical information and additional peripheral blood mononuclear cell (PBMC)
in vitro tests.
The effect of dapsone on PBMC proliferation was assessed in vitro with PBMC from the patient and a
5
healthy volunteer of same age, sex and ethnic origin. PBMC were Ficoll-isolated and 3x10 PBMC (in

triplicate) were incubated for 48 h in 100 µl of RPMI-1640 (negative controls) and in the presence of LPS
(30 µg/ml) (positive control) and dapsone at concentrations of 0.02 µM, 0.2 µM, 2 µM (typical trough
value in human serum), 20 µM and 200 µM. Proliferation was measured using the methyl thiazolyl
tetrazolium (MTT) method at 570 nm. Increased proliferation was observed in LPS treated PBMC from
both patient (35%) and healthy volunteer (44%) compared to PBMC in media only (negative controls),
whereas dapsone at concentrations 0.02–20 µM had no significant effect. Dapsone at a concentration of
200 µM had a notable inhibitory effect on cell proliferation in PBMC of both patient (–75%) and control (–
66%).

DISCUSSION
Dapsone (4-4'-diaminodiphenylsulphone), a synthetic sulfone, is a potent antimicrobial and antiinflammatory drug. Dapsone is used in first line multi-drug treatment of leprosy, for actinomycotic
mycetoma, and as an alternative agent for prophylaxis against pneumocystosis, toxoplasmosis and
malaria. Dapsone is an efficacious anti-inflammatory agent in various dermatological conditions
(dermatitis herpetiformis, acne vulgaris, urticarial vasculitis, and immunobullous diseases).
Dapsone has well recognised idiosyncratic and predictable adverse effects.1,2 The dapsone
hypersensitivity syndrome (DHS) is a severe form of DRESS syndrome (drug rash with eosinophilia and
systemic symptoms). Originally described as a triad of fever, skin eruption and internal organ
involvement, DRESS syndrome has expanded to include painful lymphadenopathy, eosinophilic
pulmonary infiltrates and myocarditis. Methaemoglobinaemia and peripheral neuropathy have also been
1
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described. DHS incidence is estimated to be 0.01–3%. This idiosyncratic reaction is possibly triggered
4
by antibody formation to haptens from dapsone metabolites, usually within 8 weeks from starting the

drug.2 Failure of physiological dapsone concentrations to activate in vitro PBMC proliferation from this
patient further supports the hypothesis for involvement of dapsone metabolites in DHS. However, the
possibility of qualitative PBMC alterations in response to dapsone or its metabolites would also be of
interest.
DIC has not been previously reported in association with dapsone, despite over 150 cases of DHS
described in the literature. DIC in this patient may be a consequence of the hypersensitivity reaction
triggering a severe systemic inflammatory response syndrome (SIRS). Severe inflammation induces
damaged endothelial and mononuclear cells to express tissue factor which triggers fibrin formation and
subsequent DIC. In intensive care units, 2% of DIC cases are attributed to inflammatory reactions to
toxins, recreational drugs, poisons, transfusion reaction or transplant rejection.5 The presence of DIC in
SIRS has important prognostic implications as coagulation abnormalities perpetuate the inflammatory
response.

The mortality among patients with severe DHS is 12–23%.3 The management of DHS is largely
supportive (fluid and electrolyte balance, haematological, fastidious skin care and prevention of
secondary infection). Steroid use remains controversial, despite case reports of benefit. Slow steroid
tapering is recommended as dapsone may persist for up to 35 days as a result of protein binding and
1
enterohepatic circulation. Thyroid function should be assessed at 3 months, since hypothyroidism due

to antimicrosomal antibodies is a late complication.
It is imperative to reduce the likelihood of DHS, by careful assessment of risk factors predisposing the
patient to this adverse event. Patients at increased risk include those with: sulphone allergy, haemolytic
anaemia, G6PD deficiency, porphyria, personal or family history of cyanosis, use of concurrent
medications metabolised by CYP3A4 and CYP2C9, rapid hydroxylators, and slow acetylators.

4

Awareness of the severe, idiosyncratic nature of dapsone reactions warrants careful monitoring of all
patients commencing dapsone therapy for early recognition of symptoms and signs suggesting this
complication.

LEARNING POINTS



Therapeutic use of dapsone can be complicated by life threatening idiosyncratic adverse reactions,
including disseminated intravascular coagulation.



Careful consideration needs to be given to whether the patient’s condition warrants dapsone and whether
the patient is at increased risk of an adverse event.



All patients commencing dapsone should be monitored closely, for early recognition of symptoms and
signs suggesting an adverse drug reaction.



The management of adverse effects from dapsone is supportive, involving management of shock, fluid
and electrolyte balance, pancytopenia, fastidious skin care and prevention of secondary infection.
Steroids may be used in severe cases not responding to supportive management.
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